<DOC>
	<DOCNO>NCT01145859</DOCNO>
	<brief_summary>The first study rivaroxaban pediatric subject Phase I study , pharmacokinetic/pharmacodynamic ( PK/PD ) profile rivaroxaban investigate confirm exposure comparable adult . This study single dose study multiple PK/PD measurement pediatric subject end Venous Thromboembolism ( VTE ) treatment .</brief_summary>
	<brief_title>Rivaroxaban Pharmacokinetics/Pharmacodynamics ( PK/PD ) Study Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Pediatric subject &gt; 6 month &lt; 18 year age time administration study drug . Patients complete treatment VTE , consider risk recurrence VTE Any major clinically relevant bleed prior VTE treatment Abnormal coagulation test within 7 day prior study drug administration Severe renal impairment Planned invasive procedure prior 24 hour study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Pediatrics</keyword>
</DOC>